First Time Loading...
L

Lonza Group AG
SIX:LONN

Watchlist Manager
Lonza Group AG
SIX:LONN
Watchlist
Price: 428 CHF +1.4% Market Closed
Updated: Oct 1, 2023

Intrinsic Value

Intrinsic Value History
Lonza Group AG

Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.

This feature available only with
Unlimited Plan

Sign up to access Lonza Group AG's intrinsic value history.

No restrictions, no limits.
All stocks, all tools.

Example
Spot Contrarian Opportunities

Look for stocks that have been historically overvalued but are now trading below their intrinsic value.

Example
Easily Identify Value Traps

Avoid stocks that are always undervalued and never reach their intrinsic value.

Example
Find Strong Rebounds

Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.

Valuation Methods

There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.

DCF Value
Discounted Cash Flow

DCF Parameters:
Operating Model
Discount Rate
Forecast Period
Terminal Growth
DCF Input
DCF Input
DCF Input

Fundamental Analysis

Financials

Balance Sheet Decomposition
Lonza Group AG

Current Assets 5.6B
Cash & Short-Term Investments 2.1B
Receivables 1.5B
Other Current Assets 1.9B
Non-Current Assets 12B
PP&E 6.6B
Intangibles 5.1B
Other Non-Current Assets 418m
Current Liabilities 2.7B
Other Current Liabilities 2.7B
Non-Current Liabilities 4.7B
Long-Term Debt 2.5B
Other Non-Current Liabilities 2.2B
Efficiency
Fundamental Scores

LONN Profitability Score
Profitability Due Diligence

Lonza Group AG's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Net Income
Exceptional 3-Years Revenue Growth
Positive 3-Year Average ROE
57/100
Profitability
Score

Lonza Group AG's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

LONN Solvency Score
Solvency Due Diligence

Lonza Group AG's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
83/100
Solvency
Score

Lonza Group AG's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LONN Price Targets Summary
Lonza Group AG

Wall Street analysts forecast LONN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LONN is 626.52 CHF with a low forecast of 328.25 CHF and a high forecast of 740.25 CHF.

Lowest
Price Target
328.25 CHF
23% Downside
Average
Price Target
626.52 CHF
46% Upside
Highest
Price Target
740.25 CHF
73% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

LONN Return Decomposition
Main factors of price return

What is price return decomposition?

LONN Price
Lonza Group AG

1M 1M
-13%
6M 6M
-21%
1Y 1Y
-13%
3Y 3Y
-25%
5Y 5Y
+29%
10Y 10Y
+589%
Annual Price Range
428
52w Low
422.1
52w High
597.8
Price Metrics
Average Annual Return 27.08%
Standard Deviation of Annual Returns 36.45%
Max Drawdown -46%
Shares Statistics
Market Capitalization 31.8B CHF
Shares Outstanding 74 490 106
Percentage of Shares Shorted
N/A

Company Profile

Lonza Group AG

Country

Switzerland

Industry

Life Sciences Tools & Services

Market Cap

31.8B CHF

Dividend Yield

0.71%

Description

Lonza Group AG engages in the supply of pharmaceutical, healthcare and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 16,218 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

Contact

BASEL-STADT
Basel
Muenchensteinerstrasse 38
+41613168111.0
https://www.lonza.com/

IPO

2002-04-03

Employees

16 218

Officers

Chief Exec. Officer
Dr. Pierre-Alain Ruffieux Ph.D.
Chief Financial Officer
Mr. Philippe Deecke
Head of Group Operations
Ms. Maria Soler Nunez
VP of Investor Relations
Mr. Dirk Oehlers
Group Gen. Counsel & Company Sec.
Mr. Andreas Bohrer
Sr. Director of Global Marketing
Ms. Jennifer Clancy
Show More
Chief HR Officer
Dr. Caroline Barth M.D.
Head of External Communications
Dr. Sanna Fowler
Show Less

See Also

Other Stocks
What is the Intrinsic Value of one LONN stock?

The intrinsic value of one LONN stock under the Base Case scenario is 525.39 CHF.

Is LONN stock undervalued or overvalued?

Compared to the current market price of 428 CHF, Lonza Group AG is Undervalued by 19%.